Peer-Reviewed Manuscripts

Please find a list of peer-reviewed manuscripts the PRCSG has completed below.

ArticleAuthor(s)JournalYear
Safety and effectiveness of abatacept in juvenile idiopathic arthritis: results from the PRINTO/PRCSG registryDaniel J. Lovell, Nikolay Tzaribachev, Michael Henrickson, Gabriele Simonini, Thomas A. Griffin, Ekaterina Alexeeva, John F. Bohnsack, Andrew Zeft, Gerd Horneff, Richard K. Vehe, Valda Stanevica, Stacey Tarvin, Maria Trachana, Ana Quintero del Rio, Adam M. Huber, Daniel Kietz, Ilonka Orban, Jason Dare, Ivan Foeldvari, Pierre Quartier, Alyssa Dominique, Teresa A. Simon, Alberto Martini, Hermine I. Brunner and Nicolino Ruperto, for the Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG)Rheumatology (Oxford). 2024 Jan 18:keae025. doi: 10.1093/rheumatology/keae025. Epub ahead of print. PMID: 38243722.2024
Long-term efficacy and safety of subcutaneous tocilizumab in clinical trials of polyarticular or systemic juvenile idiopathic arthritisHermine I. Brunner, Nicolino Ruperto, Athimalaipet V. Ramanan, Gerd Horneff, Kirsten Minden, Inmaculada Calvo Penades, Ekaterina Alexeeva, Gavin Cleary, Sara M. Stern, Isabelle Kone-Paut, María del Rocío Maldonado Velázquez, C. Egla Rabinovich, Agustin Remesal, Clovis Artur Silva, Irina Nikishina, Mauro Zucchetto, Laura Brockwell, Oliver Gordon, Sandra Nagel, Fabrizio De Benedetti, for the PRINTO and PRCSG investigatorsRheumatology (Oxford). 2024 Mar 29:keae180. doi: 10.1093/rheumatology/keae180. Epub ahead of print. PMID: 38552315.2024
S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthritisHermine I Brunner, Grant S Schulert, Alyssa Sproles, Sherry Thornton, Gabriel Vega Cornejo, Jordi Anton, Ruben Cuttica, Michael Henrickson, Ivan Foeldvari, Daniel J Kingsbury, Margarita Askelson, Jinqi Liu, Sumanta Mukherjee, Robert L Wong, Daniel J Lovell, Alberto Martini, Nicolino Ruperto, and Alexei A Grom on behalf of the Pediatric Rheumatology Collaborative Study Group (PRCSG) and the Paediatric Rheumatology International Trials Organisation (PRINTO)Arthritis Research & Therapy (2024) 26:125
https://doi.org/10.1186/s13075-024-03347-0
2024
Safety and efficacy of tofacitinib for the treatment of
patients with juvenile idiopathic arthritis: preliminary
results of an open-label, long-term extension study
Hermine I. Brunner, Jonathan Akikusa, Eslam Al-Abadi, John Bohnsack, Alina Lucica Boteanu, Gaëlle Chédeville, Ruben Cuttica, Wendy De La Pena, Lawrence Jung, Özgür Kasapçopur, Katarzyna Kobusińska, Grant Schulert, Cláudia Neiva, Rafael Rivas-Chacon, Juan Cruz Rizo Rodriguez, Mónica Vázquez0-Del Mercado, Linda Wagner-Weiner, Jennifer E Weiss, Carine Wouters, Holly Posner, Ann Wouters, Cheng Chang, Claire White, Keith S Kanik, Shixue Liu, Alberto Martini, Daniel J Lovell, Nicolino Ruperto, for the Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG)Ann Rheum Dis. 2024; 0:ard-2023-225094v1-ard-2023-2250942024
Intravenous Golimumab in Children with Polyarticular-Course Juvenile Idiopathic Arthritis: Long-term Extension of an Open-label, Phase 3 StudyHermine I. Brunner, César Pacheco-Tena, Ingrid Louw, Gabriel Vega-Cornejo, Ekaterina Alexeeva, Simone Appenzeller, Vyacheslav Chasnyk, Thomas Griffin, Carmen Navarrete Suarez, Sheila Knupp-Oliveira, Andrew Zeft, Yonatan Butbul Aviel, Deirdre De Ranieri, Beth S. Gottlieb, Deborah M. Levy, C. Egla Rabinovich, Clóvis Artur Silva, Yury Spivakovsky, Yosef Uziel, Sarah Ringold, Xie L. Xu, Jocelyn H. Leu, Edwin Lam, Yuhua Wang, Daniel J. Lovell, Alberto Martini and Nicolino Ruperto on behalf of the Pediatric Rheumatology Collaborative Study Group (PRCSG) and Paediatric Rheumatology INternational Trials Organisation (PRINTO)The Journal of Rheumatology Aug 2024, jrheum.2024-0298; DOI: 10.3899/jrheum.2024-02982024
Abatacept as Monotherapy and in Combination with Methotrexate in Patients with Juvenile Idiopathic Arthritis: Analysis of 2 Phase III Trials.Nicolino Ruperto, Daniel J. Lovell, Alberto Berman, Jordi Anton, Diego Oscar Viola, Bernard Lauwerys, Maria Elena Rama, John Bohnsack, Johannes Breedt, Michel Fischbach, Thomas Lutz, Kirsten Minden, Mahmood Ally, Nadina Rubio-Perez, Elisabeth Gervais, Riana Van Zyl, Robert Wong, Margarita Askelson, Alberto Martini, and Hermine I Brunner for the Pediatric Rheumatology Collaborative Study Group (PRCSG) and the Paediatric Rheumatology International Trials Organization (PRINTO)The Journal of Rheumatology July 2023, jrheum.2022-1320.2023
Baricitinib in juvenile idiopathic arthritis: an international multi-centre phase 3, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial.Athimalaipet V Ramanan, Pierre Quartier, Nami Okamoto, Ivan Foeldvari, Alberto Spindler, Sarka Fingerhutova, Jordi Anton, Zhongkai Wang, Gabriella Meszaros, Joana Araujo, Ran Liao, Stuart Keller, Hermine I Brunner, Nicolino Ruperto, on behalf of the JUVE-BASIS investigators and of the Paediatric Rheumatology International Trials Organisation (PRINTO)Lancet. 2023 Jul 6:S0140-6736(23)00921-2. Epub ahead of print. PMID: 374232312023
Long-Term Maintenance of Clinical Responses by Individual Patients With Polyarticular-Course Juvenile Idiopathic Arthritis Treated with Abatacept.Hermine I Brunner, Nikolay Tzaribachev, Ingrid Louw, Inmaculada Calvo Penades, Francisco Avila-Zapata, Gerd Horneff, Ivan Foeldvari, Daniel J Kingsbury, Maria Eliana Paz Gastanaga, Carine Wouters, Johannes Breedt, Robert Wong, Margarita Askelson, Joe Zhuo, Alberto Martini, Daniel J Lovell, and Nicolino Ruperto for the investigators of the PRINTO and PRCSG networksArthritis Car Res (Hoboken). 2023. Epub 2023/05/24. PubMed PMID: 372211462023
Children With Enthesitis-Related Arthritis and Possible Benefits From Treatments for Adults With SpondyloarthritisWeiss, P.F., Fuhlbrigge, R.C., von Scheven, E., Lovell, D.J., Colbert, R.A., Brunner, H.I.Arthritis Care Res, 2022. pp 1-7.2022
Patient-Reported Outcomes Among Patients Aged 2–17 Years With Polyarticular-Course Juvenile Idiopathic Arthritis Treated With Subcutaneous Abatacept: 2-Year Results From an International Phase III StudyRuperto, N., Lovell, D.J., Berman, A., Ávila-Zapata, F., Horneff, G., Alessio, M., Becker, M.L., Belot, A., Burgos-Vargas, R., Gamir, M.L., Goldenstein-Schainberg, C., Scheibel, I.M., Terreri, M.T., Zemel, L., Zhuo, J., Askelson, M., Wong, R., Martini, A., Brunner, H.I. and (2022),Arthritis Care Res. Accepted Author Manuscript. https://doi.org/10.1002/acr.249892022
Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trialBrunner HI, Foeldvari I, Alexeeva E, Ayaz NA, Calvo Penades I, Kasapcopur O, Chasnyk VG, Hufnagel M, Żuber Z, Schulert G, Ozen S, Rakhimyanova A, Ramanan A, Scott C, Sozeri B, Zholobova E, Martin R, Zhu X, Whelan S, Pricop L, Martini A, Lovell D, Ruperto N; Paediatric Rheumatology INternational Trials Organization (PRINTO) and Pediatric Rheumatology Collaborative Study Group (PRCSG).Ann Rheum Dis. 2022 Aug 12:annrheumdis-2022-222849. doi: 10.1136/ard-2022-222849. Epub ahead of print. PMID: 35961761.
2022
Evolution in the Understanding of Pediatric-Onset Axial SpondyloarthritisLovell, D.J. and Brunner, H.I.Arthritis Care Res, 73: 921-923.2021 (Editorial)
Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritisRuperto N, Brunner HI, Ramanan AV, Horneff G, Cuttica R, Henrickson M, Anton J, Boteanu AL, Penades IC, Minden K, Schmeling H, Hufnagel M, Weiss JE, Pardeo M, Nanda K, Roth J, Rubio-Pérez N, Hsu JC, Wimalasundera S, Wells C, Bharucha K, Douglass W, Bao M, Mallalieu NL, Martini A, Lovell D, De Benedetti F, for the Paediatric Rheumatology INternational Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG)Rheumatology (Oxford). 2021 Oct 2;60(10):4568-4580. doi: 10.1093/rheumatology/keab047. PMID: 335068752021
Open-Label Phase 3 Study of Intravenous Golimumab in Patients With Polyarticular Juvenile Idiopathic ArthritisRuperto N, Brunner HI, Pacheco-Tena C, Louw I, Vega-Cornejo G, Spindler AJ, Kingsbury DJ, Schmeling H, Borzutzky A, Cuttica R, Inman CJ, Malievskiy V, Scott C, Keltsev V, Terreri MT, Viola DO, Xavier RM, Fernandes TAP, Velázquez MDRM, Henrickson M, Clark MB, Bensley KA, Li X, Lo KH, Leu JH, Hsu CH, Hsia EC, Xu Z, Martini A, Lovell DJ; Pediatric Rheumatology Collaborative Study Group (PRCSG) and the Paediatric Rheumatology International Trials Organisation (PRINTO).Rheumatology (Oxford). 2021 Oct 2;60(10):4495-4507. doi: 10.1093/rheumatology/keab021. PMID: 33493312; PMCID: PMC8487314.2021
Absence of Association Between Abatacept Exposure and Initial Infection in Patients With Juvenile Idiopathic ArthritisNicolino Ruperto, Hermine I. Brunner, Nikolay Tzaribachev, Gabriel Vega-Cornejo, Ingrid Louw, Rolando Cimaz, Jason Dare, Graciela Espada, Enrique Faugier, Manuel Ferrandiz, Valeria Gerloni, Pierre Quartier, Clovis Artur Silva, Linda Wagner-Weiner, Yash Gandhi, Julie Passarell, Marleen Nys, Robert Wong, Alberto Martini, and Daniel J. Lovell, for the Pediatric Rheumatology Collaborative Study Group (PRCSG) and the Paediatric Rheumatology International Trials Organisation (PRINTO)The Journal of Rheumatology Jan 2021, jrheum.200154; DOI: 10.3899/jrheum.200154
2021
Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trialNicolino Ruperto MD, MPH*, Hermine I Brunner MD, MSc, MBA*, Olga Synoverska MD, Tracy V Ting MD, MSc, RhMSUS, Carlos Abud Mendoza MD, Alberto Spindler MD, Yulia Vyzhga MD, Katherine Marzan MD, Lyudmila Grebenkina MD, Irit Tirosh MD, Lisa Imundo MD, Rita Jerath MD, Daniel J Kingsbury MD, Betul Sozeri MD, Sheetal S Vora MD, Sampath Prahalad MD, Elena Zholobova MD, Yonatan Butbul Aviel MD, Vyacheslav Chasnyk MD, Melissa Lerman MD, Kabita Nanda MD, Heinrike Schmeling MD, Heather Tory MD, Yosef Uziel MD, Diego Oscar Viola MD, Holly B Posner MD, Keith S Kanik MD, Ann Wouters MSc, Cheng Chang PhD, Richard Zhang PhD, Irina Lazariciu MSc, Ming-Ann Hsu MPH, Ricardo M Suehiro MD, Alberto Martini MD*, and Daniel J Lovell MD, MPH*, for the Paediatric Rheumatology International Trials Organisation (PRINTO) and Pediatric Rheumatology Collaborative Study Group (PRCSG)November 09, 2021 DOI:https://doi.org/10.1016/S0140-6736(21)01255-12021
Prevalence of autoimmune diseases and other associated conditions in children and young adults with juvenile idiopathic arthritis.Lovell DJ, Huang B, Chen C, Angeles-Han S, Simon T, Brunner HI.RMD Open 2021;7:e001435. doi:10.1136/ rmdopen-2020-0014352021
Prevalence of autoimmune diseases and other associated conditions in children and young adults with juvenile idiopathic arthritis.Lovell DJ, Huang B, Chen C, Angeles-Han S, Simon T, Brunner HI.RMD Open March 2021;7(1):e001435. doi:10.1136/ rmdopen-2020-0014352021
Efficacy and Safety of Tocilizumab for Polyarticular-Course Juvenile Idiopathic Arthritis in the Open-Label Two-Year Extension of a Phase III TrialHermine I. Brunner, Nicolino Ruperto, Zbigniew Zuber, Rubén Cuttica, Vladimir Keltsev, Ricardo M. Xavier, Ruben Burgos-Vargas, et al.Arthritis & Rheumatology, March 2021.2021
Functional Ability and Health-Related Quality of Life in Randomized Controlled Trials of Tocilizumab in Patients With Juvenile Idiopathic Arthritis.Brunner HI, Chen C, Bovis F, De Benedetti F, Espada G, Joos R, Akikusa J, Chaitow J, Boteanu AL, Kimura Y, Rietschel C, Siri D, Smolewska E, Schmeling H, Brown DE, Martini A, Lovell DJ, Huang B, Ruperto N; Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG).Arthritis Care Res (Hoboken). 2021 Sep;73(9):1264-1274. doi: 10.1002/acr.24384. Epub 2021 Aug 22021
Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparisonBrunner HI, Abud-Mendoza C, Mori M, et al.RMD Open 2021;7:e001747. doi:10.1136/ rmdopen-2021-001747.2021
Tapering Canakinumab Monotherapy in Patients with Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results from an Open-label, Randomized Phase IIIb/IV Study.Quartier P, Alexeeva E, Tamàs C, Chasnyk V, Wulffraat N, Palmblad K, Wouters C, Brunner H, Marzan K, Schneider R, Horneff G, Martini A, Anton J, Wei X, Slade A, Ruperto N, Abrams K; Pediatric Rheumatology International Trials Organization (PRINTO), the Pediatric Rheumatology Collaborative Study Group (PRCSG). Arthritis Rheumatol. 2020 Aug 11. doi: 10.1002/art.41488. Epub ahead of print. PMID: 327833512020
Tocilizumab slows radiographic progression in patients with systemic or polyarticular-course juvenile idiopathic arthritis: radiographic analysis from two randomized controlled trials.Malattia C, Ruperto N, Pederzoli S, Palmisani E, Pistorio A, et al. Arthritis research & therapy 22(1):211. September 2020.2020
Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate.Lovell DJ, Brunner HI, Reiff AO, Jung L, Jarosova K, Němcová D, Mouy R, Sandborg C, Bohnsack JF, Elewaut D, Gabriel C, Higgins G, Kone-Paut I, Jones OY, Vargová V, Chalom E, Wouters C, Lagunes I, Song Y, Martini A, Ruperto N. RMD Open. 2020 Jul;6(2):e001208. doi: 10.1136/rmdopen-2020-001208. PMID: 32665432; PMCID: PMC7425194.2020
Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis With and Without Fever at Baseline: Results From an Open-Label, Active-Treatment Extension StudyHermine I. Brunner, Pierre Quartier, Ekaterina Alexeeva, Tamàs Constantin, Isabelle Koné-Paut, et al.Arthritis & Rheumatology (December 2020)2020
Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis With and Without Fever at Baseline: Results From an Open-Label, Active-Treatment Extension Study.Hermine I. Brunner, Pierre Quartier, Ekaterina Alexeeva, Tamàs Constantin, Isabelle Koné-Paut, 6 7 8 9 10 11 Katherine Marzan, Rayfel Schneider, Nico M. Wulffraat, Vyacheslav Chasnyk, Irit Tirosh, Tilmann Kallinich, 12 13 14 15 16 Jasmin Kuemmerle-Deschner, Carine Wouters, Bernard Lauwerys, Irina Nikishina, Maria Trachana, 17 18 1 19 20 21 Olga Vougiouka, Alberto Martini, Daniel J. Lovell, Jeremy Levy, Eleni Vritzali, and Nicolino Ruperto, for the Paediatric Rheumatology International Trials Organisation and the Pediatric Rheumatology Collaborative Study GroupArthritis & Rheumatology. Vol. 0, No. 0, Month 2020, pp 1–12
DOI 10.1002/art.41436
2020
Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry 7-Year Interim Results.Hermine I Brunner, Kabita Nanda, Mary Toth, Ivan Foeldvari, John Bohnsack, Diana Milojevic, C Egla Rabinovich, Daniel J Kingsbury, Katherine Marzan, Elizabeth Chalom, Gerd Horneff, Rolf-Michael Kuester, Jason A Dare, Maria Trachana, Lawrence K Jung, Judyann Olson, Kirsten Minden, Pierre Quartier, Mareike Bereswill, Jasmina Kalabic, Hartmut Kupper, Daniel J Lovell, Alberto Martini, Nicolino Ruperto, Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG).Arthritis Care & Research. Vol. 72, No. 10, October 2020 pp 1420-14302020
Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry 7-Year Interim Results.Hermine I Brunner, Kabita Nanda, Mary Toth, Ivan Foeldvari, John Bohnsack, Diana Milojevic, C Egla Rabinovich, Daniel J Kingsbury, Katherine Marzan, Elizabeth Chalom, Gerd Horneff, Rolf-Michael Kuester, Jason A Dare, Maria Trachana, Lawrence K Jung, Judyann Olson, Kirsten Minden, Pierre Quartier, Mareike Bereswill, Jasmina Kalabic, Hartmut Kupper, Daniel J Lovell, Alberto Martini, Nicolino Ruperto, Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG).Arthritis Care & Research. Vol. 72, No. 10, October 2020 pp 1420-1430. DOI 10.1002/acr.240442020
Abatacept: A Review of the Treatment of Polyarticular-Course Juvenile Idiopathic ArthritisBrunner, H.I., Wong, R., Nys, M. et al.Arthritis. Pediatr Drugs (2020).2020
Abatacept: A Review of the Treatment of Polyarticular-Course Juvenile Idiopathic Arthritis.Brunner, H.I., Wong, R., Nys, M. et al.Pediatr Drugs (2020)2020
Maintenance of antibody response to diphtheria/tetanus vaccine in patients aged 2 – 5 years with polyarticular-course juvenile idiopathic arthritis receiving subcutaneous abatacept.Brunner, H.I., Tzaribachev, N, Cornejo, G.V. et al.Pediatr Rheumatol 18, 19 (2020).2020
Efficacy and Safety of Tocilizumab for Polyarticular‐Course Juvenile Idiopathic Arthritis in the Open‐Label 2‐Year Extension of a Phase 3 Trial.Brunner, H.I., Ruperto, N., Zuber, Z., Cuttica, R., Keltsev, V., Xavier, R.M., Burgos‐Vargas, R., Calvo Penades, I., Silverman, E.D., Espada, G., Ferrandiz Zavaler, M., Kimura, Y., Duarte, C., Job‐Deslandre, C., Joos, R., Douglass, W., Wimalasundera, S., Bharucha, K.N., Wells, C., Lovell, D.J., Martini, A., De Benedetti, F.Arthritis & Rheumatology. Accepted Author Manuscript. 2020. doi:10.1002/art.415282020
Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial.Brunner HI, Abud-Mendoza C, Viola DO, Calvo Penades I, Levy D, Anton J, Calderon JE, Chasnyk VG, Ferrandiz MA, Keltsev V, Paz Gastanaga ME, Shishov M, Boteanu AL, Henrickson M, Bass D, Clark K, Hammer A, Ji BN, Nino A, Roth DA, Struemper H, Wang ML, Martini A, Lovell D, Ruperto N, in collaboration with the Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG).Annals of the Rheumatic Diseases 2020;79:1340–1348.2020
Safety and efficacy of subcutaneous tocilizumab in patients with systemic and polyarticular juvenile idiopathic arthritis.Ramanan AV, Brunner HI, Ruperto N, Martini A, Cuttica RJ, Weiss JE, Henrickson M, Schmeling H, Anton J, Minden K, Horneff G, Gamir-Gamir ML, Hufnagel M, Douglass W, Wells C, Wimalasundera S, Mallalieu NL, Lovell DJ, De Benedetti F.Rheumatology, 58: S3, April 20192019
Neutropenia During Tocilizumab Treatment Is Not Associated With Infection Risk in Systemic or Polyarticular-Course Juvenile Idiopathic Arthritis.Pardeo M, Wang J, Ruperto N, Alexeeva E, Chasnyk V, Schneider R, Horneff G, Huppertz HI, Minden K, Onel K, Zemel L, Martin A, Kone-Paut I, Siamopoulou-Mavridou A, Silva CA, Porter-Brown B, Bharucha KN, Brunner HI, De Benedetti F.J Rheumatol. Mar 2019, jrheum. 180795; DOI: 10.3899/jrheum.1807952019
Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: results from an open-label phase 1 clinical trial.Mallalieu, N.L., Wimalasundera, S., Hsu, J.C. et al.Pediatr Rheumatol (2019) 17: 57.2019
Immunome perturbation is present in patients with juvenile idiopathic arthritis who are in remission and will relapse upon anti-TNFα withdrawal.Leong JY, Chen P, Yeo JG, Ally F, Chua C, Nur Hazirah S, Poh SL, Pan L2, Lai L, Lee ESC, Bathi LDT, Arkachaisri T, Lovell D, Albani SPediatric Rheumatology Collaborative Study Group. Ann Rheum Dis. 2019 Sep 20. pii: annrheumdis-2019-216059.2019
Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry 7-Year Interim Results.Brunner, H.I., Nanda, K., Toth, M., Foeldvari, I., Bohnsack, J., Milojevic, D., Rabinovich, C.E., Kingsbury, D.J., Marzan, K., Chalom, E., Horneff, G., Kuester, R.‐M., Dare, J.A., Trachana, M., Jung, L.K., Olson, J., Minden, K., Quartier, P., Bereswill, M., Kalabic, J., Kupper, H., Lovell, D.J., Martini, A., Ruperto, N.Arthritis Care Res2019
American College of Rheumatology Provisional Criteria for Clinically Relevant Improvement in Children and Adolescents With Childhood-Onset Systemic Lupus Erythematosus.Brunner H.I., Holland M.J., Beresford M.W., Ardoin S.P., Appenzeller S., Silva C.A., Flores F., Goilav B., Avar Aydin P.O., Wenderfer S.E., Levy D.M., Ravelli A., Khubchandani R., Avcin T., Klein-Gitelman M.S., Ruperto N., Feldman B.M., Ying J.Arthritis Care Res 71: 579-590. doi:10.1002/acr.238342019
Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trialsN. Ruperto, H. I. Brunner, P. Quartier, T. Constantin, N. M. Wulffraat, G. Horneff, O. Kasapcopur, R. Schneider, J. Anton, J. Barash, R. Berner, F. Corona, R. Cuttica, M. Fouillet-desjonqueres, M. Fischbach, H. E. Foster, D. Foell, S. C. Radominski, A. V. Ramanan, R. Trauzeddel, E. Unsal, J. Levy, E. Vritzali, A. Martini and D. J. LovellAnnals of the Rheumatic Diseases, 2018;77:1710-1719.2018
Growth During Tocilizumab Therapy for Polyarticular-course Juvenile Idiopathic Arthritis: 2-year Data from a Phase III Clinical TrialK. N. Bharucha, H. I. Brunner, I. Calvo Penades, I. Nikishina, N. Rubio-Prez, S. Oliveira, K. Kobusinska, H. Schmeling, F. Sztajnbok, F. Weller-Heinemann, E. Zholobova, F. Zulian, R. Allen, J. Chaitow, J. Frane, C. Wells, N. Ruperto and F. De BenedettiThe Journal of Rheumatology, (), 2018.2018
Measuring Disease Damage and Its Severity in Childhood‐Onset Systemic Lupus Erythematosus.Holland M. J., Beresford M. W., Feldman B. M., Huggins J., Norambuena X., Silva C. A., Susic G., Sztajnbok F., Uziel Y., Appenzeller S., Ardoin S. P., Avcin T., Flores F., Goilav B., Khubchandani R., Klein‐Gitelman M., Levy D., Ravelli A., Wenderfer S. E., Ying J., Ruperto N., Brunner H. I. Arthritis Care Res, 70: 1621-1629 (11), 20182018
Subcutaneous Abatacept in Patients With Polyarticular-Course Juvenile Idiopathic ArthritisH. I. Brunner, N. Tzaribachev, G. Vega-Cornejo, I. Louw, A. Berman, I. Calvo Penades, J. Anton, F. Ávila-Zapata, R. Cuttica, G. Horneff, I. Foeldvari, V. Keltsev, D. J. Kingsbury, D. O. Viola, R. Joos, B. Lauwerys, M. E. Paz Gastanaga, M. E. Rama, C. Wouters, J. Bohnsack, J. Breedt, M. Fischbach, T. Lutz, K. Minden, T. Miraval, M. M. T. M. Ally, N. Rubio-Perez, E. Solau Gervais, R. Zyl, X. Li, M. Nys, R. Wong, S. Banerjee, D. J. Lovell, A. Martini and N. RupertoArthritis Rheumatology, 70 1144-1154 (7), 2018.2018
Pediatric Rheumatology Collaborative Study Group -- over four decades of pivotal clinical drug research in pediatric rheumatologyH. I. Brunner, L. G. Rider, D. J. Kingsbury, D. Co, R. Schneider, E. Goldmuntz, K. B. Onel, E. H. Giannini, D. J. Lovell, for the PRCSG Advisory Council, S. Peng and S. YimPediatric Rheumatology, 16 45 (1), 2018.2018
Clinical trials in children with adolescents with systemic lupus erythematosus: methodological aspects, regulatory landscape and future opportunities.Brunner HI, Martini A, Lovell DJ, Ruperto N. Annals of the Rheumatic Diseases Published Online First: 19 September 2018. doi: 10.1136/annrheumdis-2018-2131982018
Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study N. Ruperto, H. I. Brunner, Z. Zuber, N. Tzaribachev, D. J. Kingsbury, I. Foeldvari, G. Horneff, E. Smolewska, R. K. Vehe, A. Hazra, R. Wang, C. A. Mebus, C. Alvey, M. Lamba, S. Krishnaswami, T. C. Stock, M. Wang, R. Suehiro, A. Martini and D. J. LovellPediatric Rheumatology, 15 86 (1), 2017.2017
Extrapolation or controlled trials in paediatrics: the current dilemmaN. Ruperto, H. I. Brunner, D. J. Lovell and A. MartiniArchives of Disease in Childhood, 102 949-951 (10), 2017.2017
Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation SyndromeF. Minoia, F. Bovis, S. Daví, A. Insalaco, K. Lehmberg, S. Shenoi, S. Weitzman, G. Espada, Y.-J. Gao, J. Anton, T. Kitoh, O. Kasapcopur, H. Sanner, R. Merino, I. Astigarraga, M. Alessio, M. Jeng, V. Chasnyk, K. E. Nichols, Z. Huasong, C. Li, C. Micalizzi, N. Ruperto, A. Martini, R. Q. Cron, A. Ravelli and A. HorneThe Journal of Pediatrics, 189 72 - 78.e3 (Supplement C), 2017.2017
Development and initial validation of classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritisA. Ravelli, F. Minoia, S. Daví, A. Horne, F. Bovis, A. Pistorio, M. Aricó, T. Avcin, E. M. Behrens, F. De Benedetti, L. Filipovich, A. A. Grom, J.-I. Henter, N. T. Ilowite, M. B. Jordan, R. Khubchandani, T. Kitoh, K. Lehmberg, D. J. Lovell, P. Miettunen, K. E. Nichols, S. Ozen, J. Pachlopnick-Schmid, A. V. Ramanan, R. Russo, R. Schneider, G. Sterba, Y. Uziel, C. Wallace, C. Wouters, N. Wulffraat, E. Demirkaya, H. I. Brunner, A. Martini, N. Ruperto, R. Q. Cron, on behalf of the Pediatric Rheumatology International Trials Organization, the Childhood Arthritis Rheumatology Research Alliance, the Pediatric Rheumatology Collaborative Study Group and the Histiocyte Society Arthritis Rheumatology, 68 566-576 (3), 2016.2016
Rate and Clinical Presentation of Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With CanakinumabA. A. Grom, N. T. Ilowite, V. Pascual, H. I. Brunner, A. Martini, D. Lovell, N. Ruperto, for the Paediatric Rheumatology International Trials Organisation, the Pediatric Rheumatology Collaborative Study Group, K. Leon, K. Lheritier and K. AbramsArthritis Rheumatology, 68 218-228 (1), 2016.2016
Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trialH. I. Brunner, N. Ruperto, Z. Zuber, C. Keane, O. Harari, A. Kenwright, P. Lu, R. Cuttica, V. Keltsev, R. M. Xavier, I. Calvo, I. Nikishina, N. Rubio-Pérez, E. Alexeeva, V. Chasnyk, G. Horneff, V. Opoka-Winiarska, P. Quartier, C. A. Silva, E. Silverman, A. Spindler, E. Baildam, M. L. Gámir, A. Martin, C. Rietschel, D. Siri, E. Smolewska, D. Lovell, A. Martini, F. De Benedetti, for the Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG)Annals of the Rheumatic Diseases, 74 1110-1117 (6), 2015.2015
Catch-Up Growth During Tocilizumab Therapy for Systemic Juvenile Idiopathic Arthritis: Results From a Phase III TrialF. De Benedetti, H. Brunner, N. Ruperto, R. Schneider, R. Xavier, R. Allen, D. E. Brown, J. Chaitow, M. Pardeo, G. Espada, V. Gerloni, B. L. Myones, J. W. Frane, J. Wang, T. H. Lipman, K. N. Bharucha, A. Martini, D. Lovell, for the Paediatric Rheumatology International Trials Organisation and the Pediatric Rheumatology Collaborative Study GroupArthritis Rheumatology, 67 840-848 (3), 2015.2015
Long-Term Safety, Efficacy, and Quality of Life in Patients With Juvenile Idiopathic Arthritis Treated With Intravenous Abatacept for Up to Seven YearsD. J. Lovell, N. Ruperto, R. Mouy, E. Paz, N. Rubio-Pérez, C. A. Silva, C. Abud-Mendoza, R. Burgos-Vargas, V. Gerloni, J. A. Melo-Gomes, C. Saad-Magalhaes, J. Chavez-Corrales, C. Huemer, A. Kivitz, F. J. Blanco, I. Foeldvari, M. Hofer, H.-I. Huppertz, C. Job Deslandre, K. Minden, M. Punaro, A. J. Block, E. H. Giannini, A. Martini, for the Pediatric Rheumatology Collaborative Study Group and the Paediatric Rheumatology International Trials OrganisationArthritis Rheumatology, 67 2759-2770 (10), 2015.2015
Performance of Current Guidelines for Diagnosis of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic ArthritisS. Davi, F. Minoia, A. Pistorio, A. Horne, A. Consolaro, S. Rosina, F. Bovis, R. Cimaz, M. L. Gamir, N. T. Ilowite, I. Kone-Paut, S. K. Feitosa de Oliveira, D. McCurdy, C. A. Silva, F. Sztajnbok, E. Tsitsami, E. Unsal, J. E. Weiss, N. Wulffraat, M. Abinun, A. Aggarwal, M. T. Apaz, I. Astigarraga, F. Corona, R. Cuttica, G. D'Angelo, E. M. Eisenstein, S. Hashad, L. Lepore, V. Mulaosmanovic, S. Nielsen, S. Prahalad, D. Rigante, V. Stanevicha, G. Sterba, G. Susic, S. Takei, R. Trauzeddel, M. Zletni, N. Ruperto, A. Martini, R. Q. Cron, A. Ravelli and on behalf of the Paediatric Rheumatology International Trials Organisation, the Childhood Arthritis and Rheumatology Research Alliance, the Pediatric Rheumatology Collaborative Study Group, and the Histiocyte SocietyArthritis Rheumatology, 66 2871-2880 (10), 2014.2014
Safety of celecoxib and nonselective nonsteroidal anti-inflammatory drugs in juvenile idiopathic arthritis: results of the phase 4 registryR. Sobel, D. Lovell, H. Brunner, J. Weiss, P. Morris, B. Gottlieb, E. Chalom, L. Jung, K. Onel, L. Petiniot, D. Goldsmith, K. Nanda, M. Shishov, S. Abramsky, J. Young, E. Giannini and the Pediatric Rheumatology Collaborative Study GroupPediatric Rheumatology, 12 29 (1), 2014.2014
Validation of the systemic lupus erythematosus responder index for use in juvenile-onset systemic lupus erythematosusR. Mina, M. S. Klein-Gitelman, S. Nelson, B. A. Eberhard, G. Higgins, N. G. Singer, K. Onel, L. Tucker, K. M. O'Neil, M. Punaro, D. M. Levy, K. Haines, A. Martini, N. Ruperto, D. Lovell and H. I. BrunnerAnnals of the Rheumatic Diseases, 73 401-406 (2), 2014.2014
Determinants of Health-Related Quality of Life in Children Newly Diagnosed With Juvenile Idiopathic ArthritisM. Seid, B. Huang, S. Niehaus, H. I. Brunner and D. J. LovellArthritis Care Research, 66 263-269 (2), 2014.2014
Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 yearsD. J. Kingsbury, B. Bader-Meunier, G. Patel, V. Arora, J. Kalabic and H. KupperClinical Rheumatology, 1-9 (), 2014.2014
Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic ArthritisN. Ruperto, H. I. Brunner, P. Quartier, T. Constantin, N. Wulffraat, G. Horneff, R. Brik, L. McCann, O. Kasapcopur, L. Rutkowska-Sak, R. Schneider, Y. Berkun, I. Calvo, M. Erguven, L. Goffin, M. Hofer, T. Kallinich, S. K. Oliveira, Y. Uziel, S. Viola, K. Nistala, C. Wouters, R. Cimaz, M. A. Ferrandiz, B. Flato, M. L. Gamir, I. Kone-Paut, A. Grom, B. Magnusson, S. Ozen, F. Sztajnbok, K. Lheritier, K. Abrams, D. Kim, A. Martini and D. J. LovellNew England Journal of Medicine, 367 2396-2406 (25), 2012.2012
Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic ArthritisF. De Benedetti, H. I. Brunner, N. Ruperto, A. Kenwright, S. Wright, I. Calvo, R. Cuttica, A. Ravelli, R. Schneider, P. Woo, C. Wouters, R. Xavier, L. Zemel, E. Baildam, R. Burgos-Vargas, P. Dolezalova, S. M. Garay, R. Merino, R. Joos, A. Grom, N. Wulffraat, Z. Zuber, F. Zulian, D. Lovell and A. MartiniNew England Journal of Medicine, 367 2385-2395 (25), 2012.2012
Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritisC. A. Wallace, E. H. Giannini, S. J. Spalding, P. J. Hashkes, K. M. O'Neil, A. S. Zeft, I. S. Szer, S. Ringold, H. I. Brunner, L. E. Schanberg, R. P. Sundel, D. Milojevic, M. G. Punaro, P. Chira, B. S. Gottlieb, G. C. Higgins, N. T. Ilowite, Y. Kimura, S. Hamilton, A. Johnson, B. Huang, D. J. Lovell, for the Childhood Arthritis and R. R. AllianceArthritis Rheumatism, 64 2012-2021 (6), 2012.2012
Measuring process of arthritis care: A proposed set of quality measures for the process of care in juvenile idiopathic arthritisD. J. Lovell, M. H. Passo, T. Beukelman, S. L. Bowyer, B. S. Gottlieb, M. Henrickson, N. T. Ilowite, Y. Kimura, E. M. DeWitt, J. Segerman, L. D. Stein, J. Taylor, R. K. Vehe and E. H. GianniniArthritis Care Research, 63 10-16 (1), 2011.2011
American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritisC. A. Wallace, E. H. Giannini, B. Huang, L. Itert, N. Ruperto, C. A. R. R. A. (CARRA), P. R. C. S. G. (PRCSG) and P. R. I. T. O. (PRINTO)Arthritis Care Research, 63 929-936 (7), 2011.2011
Clinical trial safety and mortality analyses in patients receiving etanercept across approved indicationsA. B. Gottlieb, K. Gordon, E. H. Giannini, P. Mease, J. Li, Y. Chon, J. Maddox, H. H. Weng, J. Wajdula, S. L. Lin and S. W. BaumgartnerJ Drugs Dermatol, 10 289-300 (), 2011.2011
The effect of infliximab plus methotrexate on the modulation of inflammatory disease markers in juvenile idiopathic arthritis: analyses from a randomized, placebo-controlled trialS. Visvanathan, C. Wagner, J. C. Marini, D. J. Lovell, A. Martini, R. Petty, R. Cuttica, P. Woo, G. Espada, M. Gattorno, M. T. Apaz, E. Baildam, A. Fasth, V. Gerloni, P. Lahdenne, P. Quartier, R. Saurenmann, S. Travers, A. Mendelsohn, S. Xu, E. H. Giannini and N. RupertoPediatr Rheumatol Online J, 8 24 (), 2010.2010
EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteriaS. Ozen, A. Pistorio, S. M. Iusan, A. Bakkaloglu, T. Herlin, R. Brik, A. Buoncompagni, C. Lazar, I. Bilge, Y. Uziel, D. Rigante, L. Cantarini, M. O. Hilario, C. A. Silva, M. Alegria, X. Norambuena, A. Belot, Y. Berkun, A. I. Estrella, A. N. Olivieri, M. G. Alpigiani, I. Rumba, F. Sztajnbok, L. Tambic-Bukovac, L. Breda, S. Al-Mayouf, D. Mihaylova, V. Chasnyk, C. Sengler, M. Klein-Gitelman, D. Djeddi, L. Nuno, C. Pruunsild, J. Brunner, A. Kondi, K. Pagava, S. Pederzoli, A. Martini, N. Ruperto and for the Paediatric Rheumatology International Trials Organisation (PRINTO)Annals of the Rheumatic Diseases, 69 798-806 (5), 2010.2010
Summary of worldwide pediatric malignancies reported after exposure to etanerceptP. McCroskery, C. A. Wallace, D. J. Lovell, S. Stryker, N. Chernyukhin, C. Blosch and D. J. ZackPediatr Rheumatol Online J, 8 18 (), 2010.2010
Is it time to move to active comparator trials in juvenile idiopathic arthritis?: A review of current study designsN. Ruperto, E. H. Giannini, A. Pistorio, H. I. Brunner, A. Martini and D. J. LovellArthritis Rheumatism, 62 3131-3139 (11), 2010.2010
Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extensionN. Ruperto, D. Lovell, R. Cuttica, P. Woo, S. Meiorin, e. a. , P. R. I. T. O. (P. and P. R. C. S. G. (PRCSG)Ann Rheum Dis, 4 712-22 (), 2010.2010
Abatacept improves health-related quality of life, pain, sleep quality, and daily participation in subjects with juvenile idiopathic arthritisN. Ruperto, D. J. Lovell, T. Li, F. Sztajnbok, C. Goldenstein-Schainberg, M. Scheinberg, I. C. Penades, M. Fischbach, J. O. Alcala, P. J. Hashkes, C. Hom, L. Jung, L. Lepore, S. Oliveira, C. Wallace, M. Alessio, P. Quartier, E. Cortis, A. Eberhard, G. Simonini, I. Lemelle, E. C. Chalom, L. H. Sigal, A. Block, A. Covucci, M. Nys, A. Martini and E. H. GianniniArthritis Care Research, 62 1542-1551 (11), 2010.2010
Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritisN. Ruperto, D. J. Lovell, P. Quartier, E. Paz, N. Rubio-Pérez, C. A. Silva, C. Abud-Mendoza, R. Burgos-Vargas, V. Gerloni, J. A. Melo-Gomes, C. Saad-Magalhães, J. Chavez-Corrales, C. Huemer, A. Kivitz, F. J. Blanco, I. Foeldvari, M. Hofer, G. Horneff, H.-I. Huppertz, C. Job-Deslandre, A. Loy, K. Minden, M. Punaro, A. F. Nunez, L. H. Sigal, A. J. Block, M. Nys, A. Martini and E. H. GianniniArthritis Rheumatism, 62 1792-1802 (6), 2010.2010
The Paediatric Rheumatology International Trials Organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositisN. Ruperto, A. Pistorio, A. Ravelli, L. G. Rider, C. Pilkington, S. Oliveira, N. Wulffraat, G. Espada, S. Garay, R. Cuttica, M. Hofer, P. Quartier, J. Melo-Gomes, A. M. Reed, M. Wierzbowska, B. M. Feldman, M. Harjacek, H.-I. Huppertz, S. Nielsen, B. Flato, P. Lahdenne, H. Michels, K. J. Murray, L. Punaro, R. Rennebohm, R. Russo, Z. Balogh, M. Rooney, L. M. Pachman, C. Wallace, P. Hashkes, D. J. Lovell, E. H. Giannini, B. A. Gare and A. MartiniArthritis Care Research, 62 1533-1541 (11), 2010.2010
Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritisE. H. Giannini, N. T. Ilowite, D. J. Lovell, C. A. Wallace, C. E. Rabinovich, A. Reiff, G. Higgins, B. Gottlieb, P. R. C. S. Group, Y. Chon, N. Zhang and S. W. BaumgartnerArthritis Rheumatism, 62 3259-3264 (11), 2010.2010
Juvenile idiopathic arthritis: state of the art and future perspectivesA. Martini and D. LovellAnn Rheum Dis, (7) 1260-3 (), 2010.2010
A prospecitive study comparing celecoxib with naproxen in children with juvenile rheumatoid arthritisI. Foeldvari, I. Szer, L. Zemel, D. Lovell and E. GianniniJ Rheumatol, 36 (1) 174-82 (), 2009.2009
Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseasesG. Burmester, P. Mease, B. Dinkmans, K. Gordon and D. LovellAnn Rheum Dis, 1863-9 (), 2009.2009
Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritisE. Giannini, N. Ilowite, D. Lovell, C. Wallace, C. Rabinovich and e. a.Arthritis Rheum, 60 2794-804 (9), 2009.2009
Efficacy and safety of abatacept in children with juvenile idiopathic arthritis: A randomized, double-blink, placebo controlled withdrawal trialN. Ruperto, D. Lovell, E. Giannini and A. MartiniLancet, 372 383-391 (), 2008.2008
Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trialN. Ruperto, D. Lovell and E. GianniniLancet, 372 (9636) 383-391 (), 2008.2008
The provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League Against Rheumatism Disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: A prospective validation study.N. Ruperto, A. Ravelli, A. Pistorio, V. Ferriani, I. Calvo, G. Ganser, J. Brunner, G. Dannecker, C. Silva, V. Stanevicha, R. Cate, L. van Suijlekom-Smit, O. Voygioyka, M. Fischbach, I. Foeldvari, O. Hilario, C. Modesto, R. Saurenmann, M. Sauvain, I. Scheibel, D. Sommelet, L. Tambic-Bukovac, R. Barcellona, R. Brik, S. Ehl, M. Jovanovic, J. Rovensky, F. Bagnasco, D. Lovell and A. MartiniArthritis Rheum, 59 (1) 4-13 (), 2008.2008
Safety and Efficacy of up to 8 years of continuous etanercept therapy in patients with juvenile rheumatoid arthritise. a. Lovell DJ, A. Reiff, N. Ilowite, C. Wallace, Y. Chon, S. Lin, S. Baumgartner and E. GianniniArthritis Rheum, 58 1496-504 ((5)), 2008.2008
A randomized, placebo-controlled trial of adalimumab with or without methotrexate in children with polyarticular juvenile rheumatoid arthritisD. Lovell, N. Ruperto, S. Goodman, A. Reiff, L. Jung, K. Jarosova, D. Nemcova, R. Mouy, C. Sandborg, J. Bohnsack, D. Elewaut, I. Foeldvari, V. Gerloni, J. Rovensky, K. Minden, R. Vehe, L. Wagner-Weiner, G. Horneff, H. Huppertz, N. Olson, J. Medich, R. Carcereri-De-Prati, M. McIlraith, E. Giannini and A. MartiniN Engl J Med, Vol. 359 810-820 (No. 8), 2008.2008
Adalimumab with or without methotrexate in juvenile rheumatoid arthritisD. Lovell, N. Ruperto, S. Goodman and A. ReiffN Engl J Med, 359 (8) 810-820 (), 2008.2008
A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritisN. Ruperto, D. Lovell, R. Cuttica, N. Wilkinson, P. Woo, G. Espada, C. Wouters, E. Silverman, Z. Balogh, M. Henrickson, M. Apaz, E. Baildam, A. Fasth, V. Gerloni, P. Lahdenne, A. Prieur, A. Ravelli, R. Saurenmann, M. Gamir, N. Wulffraat, L. Marodi, R. Petty, R. Joos, F. Zulian, D. McCurdy, B. Myones, K. Nagy, P. Reuman, I. Szer, S. Travers, A. Beutler, G. Keenan, J. Clark, S. Visvanathan, A. Fasanmade, A. Raychaudhuri, A. Mendelsohn, A. Martini and E. GianniniArthritis Rheum, 56 3096-3106 (), 2007.2007
Cyclosporine A in juvenile idiopathic arthritis. Results of the PRCSG/PRINTO phase IV post marketing surveillance study.N. Ruperto, A. Ravelli, E. Castell, V. Gerloni, R. Haefner, C. Malattia, F. Kanakoudi-Tsakalidou, S. Nielsen, J. Bohnsack, D. Gibbas, R. Rennebohm, O. Voygioyka, Z. Balogh, L. Lepore, E. Macejkova, N. Wulffraat, S. Oliveira, R. Russo, A. Buoncompagni, M. O. Hilario, M. G. Alpigiani, M. Passo, D. J. Lovell, R. Merino, A. Martini and E. H. GianniniClin Exp Rheumatol, 24 599-605 (5), 2006.2006
Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritisD. Lovell, A. Reiff and O. JonesArthritis Rheumatism, 54 1987-1994 (), 2006.2006
Evaluation of the comparative efficacy and tolerability of rofecoxib and naproxen in children and adolescents with juvenile rheumatoid arthritis: a 12-week randomized controlled clinical trial with a 52-week open-label extension.A. Reiff, D. Lovell, J. Van Adelsberg, M. Kiss, S. Goodman, M. Zavaler, P. Chen, J. Bolognese, P. Cavanaugh Jr, A. Reicin and E. GianniniJ Rheumatol, 33 985-995 (5), 2006.2006
International consensus on preliminary definitions of improvement in adult and juvenile myositis.L. Rider, E. Giannini, H. Brunner, N. Ruperto, L. James-Newton, A. Reed, P. Lachenbruch and F. MillerArthritis Rheum, 50 2281-90 (7), 2004.2004
Preliminary criteria for clinical remission for selected categories of juvenile idiopathic arthritisC. Wallace, N. Ruperto and E. GianniniJ Rheumatol, 31 2290-2294 (), 2004.2004
Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis.N. Ruperto, A. Ravelli, K. Murray, D. Lovell, B. Andersson-Gare, B. Feldman, S. Garay, W. Kuis, C. Machado, L. Pachman, A. Prieur, L. Rider, E. Silverman, E. Tsitsami, P. Woo, E. Giannini and A. MartiniRheumatology (Oxford), 42 1452-9 (12), 2003.2003
Defining Clinical Improvement in Adult and Juvenile MyositisL. Rider, E. Giannini, M. Harris-Love, G. Joe, D. Isenberg, C. Pilkington, P. Lachenbruch and F. MillerJ Rheumatol, 30 603-617 ((3)), 2003.2003
Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial.D. Lovell, E. Giannini, A. Reiff, O. Jones, R. Schneider, J. Olson, L. Stein, A. Gedalia, N. Ilowite, C. Wallace, M. Lange, B. Finck and D. BurgeArthritis Rheum, 48 218-26 (1), 2003.2003
Preliminary definitions of disease flare in juvenile rheumatoid arthritis (JRA).H. Brunner, D. Lovell, B. Finck and E. GianniniJ Rheumatol, 29 1058-64 (), 2002.2002
Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group.D. Lovell, E. Giannini, A. Reiff, G. Cawkwell, E. Silverman, J. Nocton, L. Stein, A. Gedalia, N. Ilowite, C. Wallace, J. Whitmore and B. FinckN Engl J Med, 342 763-9 (11), 2000.2000
Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. The Juvenile Dermatomyositis Disease Activity Collaborative Study Group.D. J. Lovell, C. B. Lindsley, R. M. Rennebohm, S. H. Ballinger, S. L. Bowyer, E. H. Giannini, J. E. Hicks, J. E. Levinson, R. Mier, L. M. Pachman, M. H. Passo, M. D. Perez, A. M. Reed, K. N. Schikler, M. Smith, L. S. Zemel and L. G. RiderArthritis Rheum, 42 2213-9 (10), 1999.1999
Long-term health outcomes and quality of life in American and Italian inception cohorts of patients with juvenile rheumatoid arthritis. I. Outcome statusN. Ruperto, J. Levinson, A. Ravelli, E. Shear, B. Tague, K. Murray, A. Martini and E. GianniniJ Rheumatol, 24 945-951 (), 1997.1997
Preliminary definition of improvement in juvenile arthritis.E. H. Giannini, N. Ruperto, A. Ravelli, D. J. Lovell, D. T. Felson and A. MartiniArthritis Rheum, 40 1202-9 (7), 1997.1997
Redundancy of conventional articular response variables used in juvenile chronic arthritis clinical trials.N. Ruperto and E. H. GianniniAnn Rheum Dis, 55 73-5 (1), 1996.1996
Intravenous immunoglobulin in the treatment of polyarticular juvenile rheumatoid arthritis: a phase I/II study. Pediatric Rheumatology Collaborative Study Group.E. H. Giannini, D. J. Lovell, E. D. Silverman, R. P. Sundel, B. L. Tague and N. RupertoJ Rheumatol, 23 919-24 (5), 1996.1996
FDA draft guidelines for the clinical evaluation of anti-inflammatory and anti-rheumatic drugs in children. Executive summary.E. H. Giannini, D. J. Lovell and B. HepburnArthritis Rheum, 38 715-8 (5), 1995.1995
Intravenous immunoglobulin in the treatment of systemic juvenile rheumatoid arthritis: a randomized placebo controlled trial. Pediatric Rheumatology Collaborative Study Group.E. D. Silverman, G. D. Cawkwell, D. J. Lovell, R. M. Laxer, T. J. Lehman, M. H. Passo, L. S. Zemel and E. H. GianniniJ Rheumatol, 21 2353-8 (12), 1994.1994
Comparative efficacy and safety of advanced drug therapy in children with juvenile rheumatoid arthritis.E. H. Giannini, J. T. Cassidy, E. J. Brewer, A. Shaikov, A. Maximov and N. KuzminaSemin Arthritis Rheum, 23 34-46 (1), 1993.1993
Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children's Study Group.E. H. Giannini, E. J. Brewer, N. Kuzmina, A. Shaikov, A. Maximov, I. Vorontsov, C. W. Fink, A. J. Newman, J. T. Cassidy and L. S. ZemelN Engl J Med, 326 1043-9 (16), 1992.1992
Auranofin therapy for juvenile rheumatoid arthritis: results of the five-year open label extension trial.E. H. Giannini, K. S. Barron, C. H. Spencer, D. A. Person, J. Baum, B. H. Bernstein, D. W. Kredich, J. C. Jacobs, L. S. Zemel and D. GibbasJ Rheumatol, 18 1240-2 (8), 1991.1991
Auranofin in the treatment of juvenile rheumatoid arthritis. Results of the USA-USSR double-blind, placebo-controlled trial. The USA Pediatric Rheumatology Collaborative Study Group. The USSR Cooperative Children's Study Group.E. H. Giannini, E. J. J. Brewer, N. Kuzmina, A. Shaikov and B. WallinArthritis Rheum, 33 466-76 (4), 1990.1990
Ibuprofen suspension in the treatment of juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group.E. Giannini, E. Brewer, M. Miller, D. Gibbas, M. Passo, H. Hoyeraal, B. Bernstein, D. Person, C. Fink and L. SawyerJ Pediatr, 117 645-52 (4), 1990.1990
HLA-B27-associated arthropathy in childhood: Long-term clinical and diagnostic outcome.K. A. Sheerin, E. H. Giannini, E. J. J. Brewer and K. S. BarronArthritis Rheum, 31 1165-70 (9), 1988.1988
Arthritis/arthralgia and hypermobility of the joints in schoolchildren.I. L. Arroyo, E. J. Brewer and E. H. GianniniJ Rheumatol, 15 978-80 (6), 1988.1988
Characteristics of responders and nonresponders to slow-acting anti-rheumatic drugs (SAARDs) in juvenile rheumatoid arthritis.E. H. Giannini, E. J. Brewer, N. Kuzmina, L. Alekseev and B. P. ShokhArthritis Rheum, 31 15-20 (1), 1988.1988
Temporal patterns of response to D-penicillamine, hydroxychloroquine, and placebo in juvenile rheumatoid arthritis patients.C. van Kerckhove, E. H. Giannini and D. J. LovellArthritis Rheum, 31 1252-8 (10), 1988.1988
Poor correlation between the erythrocyte sedimentation rate and clinical activity in juvenile rheumatoid arthritis.E. H. Giannini and E. J. BrewerClin Rheumatol, 6 197-201 (2), 1987.1987
Long-term auranofin therapy in patients with juvenile rheumatoid arthritisE. Giannini, E. Brewer, D. Person and X. HeJ Rheumatol, 314 1269-1276 (), 1986.1986
Penicillamine and hydroxychloroquine in the treatment of severe juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind placebo-controlled trial.E. Brewer, E. Giannini, N. Kuzmina and L. AlekseevN Engl J Med, 314 1269-76 (20), 1986.1986
A once-daily anti-inflammatory drug, oxaprozin, in the treatment of juvenile rheumatoid arthritis. The Pediatric Rheumatology Collaborative Study Group.J. C. Bass, B. H. Athreya, E. J. Brewer, E. H. Giannini, D. P. Goldsmith, J. R. Hollister, D. W. Kredich, N. E. Brandstrup, J. J. Miller and L. M. PachmanJ Rheumatol, 12 384-6 (2), 1985.1985
Hypermobility of the joints in juvenile episodic arthritis/arthralgia.A. Gedalia, D. A. Person, E. J. J. Brewer and E. H. GianniniJ Pediatr, 107 873-6 (6), 1985.1985
Blood gold concentrations in children with juvenile rheumatoid arthritis undergoing long-term oral gold therapy.E. H. Giannini, E. J. Brewer and D. A. PersonAnn Rheum Dis, 43 228-31 (2), 1984.1984
Time course of response to non-steroidal anti-inflammatory drugs in juvenile rheumatoid arthritis.D. J. Lovell, E. H. Giannini and E. J. J. BrewerArthritis Rheum, 27 1433-7 (12), 1984.1984
Early experiences with auranofin in juvenile rheumatoid arthritis.E. J. J. Brewer, E. H. Giannini and D. A. PersonAm J Med, 75 152-6 (6A), 1983.1983
Auranofin in the treatment of juvenile rheumatoid arthritis.E. H. Giannini, E. J. J. Brewer and D. A. PersonAJ Pediatr, 102 138-41 (1), 1983.1983
Blood and serum concentrations of gold after a single dose of auranofin in children with juvenile rheumatoid arthritis.E. H. Giannini, D. A. Person, E. J. Brewer and D. B. ParksJ Rheumatol, 10 496-8 (3), 1983.1983
Pirprofen (Rengasil) in the treatment of juvenile rheumatoid arthritis. A segment I study.J. Bass, E. Giannini, E. Brewer, B. Athreya, N. Brandstrup, D. Goldsmith, J. Miller and L. PachmanJ Rheumatol, 9 140-3 (1), 1982.1982
Ketoprofen (Orudis) in the treatment of juvenile rheumatoid arthritis. A segment I studyE. J. Brewer, E. H. Giannini, J. Baum, B. Bernstein, C. W. Fink, J. G. Schaller and C. M. KneeJ Rheumatol, 9 144-148 (1), 1982.1982
Aspirin and fenoprofen (Nalfon) in the treatment of juvenile rheumatoid arthritis results of the double blind-trial. A segment II studyE. J. Brewer, E. H. Giannini, J. Baum, B. Bernstein, C. W. Fink, H. M. Emery and J. G. SchallerJ Rheumatol, 9 123-128 (1), 1982.1982
Standard methodology for Segment I, II, and III Pediatric Rheumatology Collaborative Study Group studies. I. Design.E. J. Brewer and E. H. GianniniJ Rheumatol, 9 109-13 (1), 1982.1982
Standard methodology for Segment I, II, and III Pediatric Rheumatology Collaborative Study Group studies. II. Analysis and presentation of dataE. H. Giannini and E. J. BrewerJ Rheumatol, 9 114-122 (1), 1982.1982
Sodium meclofenamate (Meclomen) in the treatment of juvenile rheumatoid arthritis. A segment I study.E. Brewer, E. Giannini, J. Baum, J. Cassidy, C. Fink, V. Hanson, J. Jacobs and J. SchallerJ Rheumatol, 9 129-134 (), 1982.1982
Proquazone (Biarsan) in the treatment of juvenile rheumatoid arthritis. A segment I study.E. Brewer, E. Giannini, J. Baum, C. Fink, V. Hanson, J. Jacobs and J. SchallerJ Rheumatol, 9 135-139 (), 1982.1982
Plasma exchange in selected patients with juvenile rheumatoid arthritis.E. Brewer, R. Nickeson, R. Rossen, D. Person, E. Giannini and J. MilamJ Pediatr, 98 194-200 (), 1981.1981
Plasma exchange therapy of a childhood onset dermatomyositis patient.E. Brewer, E. Giannini, R. Rossen, B. Patten and E. BarkleyArthritis Rheum, 23 509-513 (), 1980.1980
Gold Therapy in the Management of Juvenile Rheumatoid ArthritisE. Brewer, E. Giannini and E. BarkleyArthritis Rheum, 23 404-411 (), 1980.1980
Comparison of tometin sodium and aspirin in the treatment of juvenile rheumatoid arthritisJ. Levinson, J. Baum, E. Brewer Jr, C. Fink, V. Hanson and J. SchallerJ Pediatr, 91 799-804 (5), 1977.1977